Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06998966 · ClinicalTrials.gov registry record · NA
Optimizing Proton Pump Inhibitors (PPI) Prescribing With EHR-Based Decision Support
A NA study of Prescribing Patterns, Physician and Physician's Practice Patterns, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- NA
- Development phase
- 372
- Enrollment target
- 1
- Study location
NCT06998966: Recruiting NA study of Prescribing Patterns, Physician and Physician's Practice Patterns, sponsored by University of California, Los Angeles.
NCT06998966 is a NA study of Prescribing Patterns, Physician and Physician's Practice Patterns that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 372 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06998966, a NA study of Prescribing Patterns, Physician and Physician's Practice Patterns, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- NA
- Development phase
- 372 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed study is a quality improvement initiative designed to rigorously evaluate new variations of UCLA Health's proton pump inhibitor (PPI) order panels, building on internal quality improvement efforts to optimize prescribing workflows within the Electronic Health Record (EHR). PPIs are notoriously overprescribed, and the study team has identified that the CareConnect default prescription setting of 90 days with three refills (360 pill days) exceed standard guidelines (in most cases, 60 pill days). It is unclear whether this is the most appropriate workflow. Given that deprescribing PPIs carries minimal risk for most patients, this initiative will assess whether modifying defaulted prescription lengths influences prescribing behavior while ensuring physicians retain full decision-making authority. This evaluation of PPI order panel variations is embedded within UCLA's existing EHR system, ensuring that changes are tested pragmatically within routine workflows. The study aims to determine whether small adjustments to the order panel can better align prescribing patterns with clinical best practices while maintaining physician autonomy.
Primary Outcome
The study will take place within the existing UCLA Health Electronic Health Record (EHR) infrastructure. Data will be automatically collected from the EHR, focusing on pill days in excess of guidelines. The trial team will validate an eMeasure of inappropriate prescriptions as the primary outcome.
Conditions Studied
Interventions
- BEHAVIORAL Algorithmic Defaulting (Indication-Based Default)
- BEHAVIORAL Active Physician Choice
Study Locations (1)
California
- UCLA Health System - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2026-01 |
| Est. Completion | 2027-01 |
| Phase | NA |
What NCT06998966 shows while recruiting
NCT06998966 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 3 conditions, with Prescribing Patterns, Physician appearing as the primary indexed condition, and to 2 interventions - of which Algorithmic Defaulting (Indication-Based Default) is the first listed.
NCT06998966 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06998966 about?
NCT06998966 is a clinical study titled "Optimizing Proton Pump Inhibitors (PPI) Prescribing With EHR-Based Decision Support". The proposed study is a quality improvement initiative designed to rigorously evaluate new variations of UCLA Health's proton pump inhibitor (PPI) order panels, building on internal quality improvement efforts to optimize prescribing workflows within the Electronic Health Record (EHR). PPIs are noto...
What is the current status of trial NCT06998966?
This trial is currently recruiting. It is a NA study. The enrollment target is 372 participants. The study started on 2026-01. Estimated completion is 2027-01.
What conditions does trial NCT06998966 study?
This clinical trial studies the following conditions: Prescribing Patterns, Physician, Physician's Practice Patterns, Drug Utilization Review.
What interventions are being tested in trial NCT06998966?
The interventions under investigation include: Algorithmic Defaulting (Indication-Based Default) (BEHAVIORAL), Active Physician Choice (BEHAVIORAL).
Who is sponsoring clinical trial NCT06998966?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06998966 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06998966's enrollment target sits among peer trials
372 280th of 2000 higher than 1,721 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia